SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Frisell J.)
 

Sökning: WFRF:(Frisell J.) > (2015-2019) > Survival and axilla...

  • de Boniface, J.Karolinska Institutet,Karolinska Institute,Capio St Gorans Hosp, Dept Surg, Stockholm, Sweden.;Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden. (författare)

Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial

  • Artikel/kapitelEngelska2017

Förlag, utgivningsår, omfång ...

  • 2017-05-26
  • Springer Science and Business Media LLC,2017
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:gup.ub.gu.se/254855
  • https://gup.ub.gu.se/publication/254855URI
  • https://doi.org/10.1186/s12885-017-3361-yDOI
  • https://lup.lub.lu.se/record/7cdb84ad-43b2-44cd-b42f-49db5f31dd7cURI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-326229URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-136328URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:135917939URI

Kompletterande språkuppgifter

  • Språk:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Background: The role of axillary lymph node dissection (ALND) has increasingly been called into question among patients with positive sentinel lymph nodes. Two recent trials have failed to show a survival difference in sentinel node-positive breast cancer patients who were randomized either to undergo completion ALND or not. Neither of the trials, however, included breast cancer patients undergoing mastectomy or those with tumors larger than 5 cm, and power was debatable to show a small survival difference. Methods: The prospective randomized SENOMAC trial includes clinically node-negative breast cancer patients with up to two macrometastases in their sentinel lymph node biopsy. Patients with T1-T3 tumors are eligible as well as patients prior to systemic neoadjuvant therapy. Both breast-conserving surgery and mastectomy, with or without breast reconstruction, are eligible interventions. Patients are randomized 1: 1 to either undergo completion ALND or not by a web-based randomization tool. This trial is designed as a non-inferiority study with breast cancer-specific survival at 5 years as the primary endpoint. Target accrual is 3500 patients to achieve 80% power in being able to detect a potential 2.5% deterioration of the breast cancer-specific 5-year survival rate. Follow-up is by annual clinical examination and mammography during 5 years, and additional controls after 10 and 15 years. Secondary endpoints such as arm morbidity and health-related quality of life are measured by questionnaires at 1, 3 and 5 years. Discussion: Several large subgroups of breast cancer patients, such as patients undergoing mastectomy or those with larger tumors, have not been included in key trials; however, the use of ALND is being questioned even in these groups without the support of high-quality evidence. Therefore, the SENOMAC Trial will investigate the need of completion ALND in case of limited spread to the sentinel lymph nodes not only in patients undergoing any breast surgery, but also in neoadjuvantly treated patients and patients with larger tumors.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Frisell, J.Karolinska Institutet,Karolinska Institute,Karolinska University Hospital,Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden.;Karolinska Univ Hosp, Dept Breast & Endocrine Surg, Stockholm, Sweden. (författare)
  • Andersson, YvetteUppsala universitet,Uppsala University,Uppsala University Hospital,Centrum för klinisk forskning, Västerås,Vastmanland Cty Hosp, Dept Surg, Vasteras, Sweden(Swepub:uu)yvean239 (författare)
  • Bergkvist, LeifUppsala universitet,Uppsala University,Centrum för klinisk forskning, Västerås(Swepub:uu)leber451 (författare)
  • Ahlgren, J.Örebro University,Univ Orebro, Dept Oncol, Orebro, Sweden. (författare)
  • Rydén, LisaLund University,Lunds universitet,Kirurgi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Bröstcancerkirurgi,Forskargrupper vid Lunds universitet,The Liquid Biopsy och Tumörprogression i Bröstcancer,Surgery (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Breast Cancer Surgery,Lund University Research Groups,The Liquid Biopsy and Tumor Progression in Breast Cancer,Skåne University Hospital,Lund Univ, Inst Clin Sci, Dept Surg, Lund, Sweden.;Skane Univ Hosp, Dept Surg, Lund, Sweden.(Swepub:lu)pat-lry (författare)
  • Olofsson Bagge, Roger,1978Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för kirurgi,Institute of Clinical Sciences, Department of Surgery,Sahlgrenska Academy,Univ Gothenburg, Sahlgrenska Univ Hosp, Inst Clin Sci, Dept Surg,Sahlgrenska Acad, Gothenburg, Sweden.(Swepub:gu)xoloro (författare)
  • Sund, MalinUmeå universitet,Umeå University,Surgery Center, Norrland University Hospital, Umeå, Sweden,Norrland Univ Hosp, Surg Ctr, Umea, Sweden.;Umea Univ, Dept Surg & Perioperat Sci, Umea, Sweden.,Institutionen för kirurgisk och perioperativ vetenskap(Swepub:umu)masu0021 (författare)
  • Johansson, H.Karolinska Institutet (författare)
  • Lundstedt, D.Sahlgrenska University Hospital,Sahlgrens Univ Hosp, Dept Oncol, Gothenburg, Sweden. (författare)
  • Karolinska InstituteCapio St Gorans Hosp, Dept Surg, Stockholm, Sweden.;Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:BMC Cancer: Springer Science and Business Media LLC171471-2407

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy